Comments
Cadila Healthcare Ltd (Zydus Cadila) said here on Tuesday that it has received the final approval from the USFDA to market Entecavir cablets in the strengths of 0.5 mg and 1 mg. The drug is used in the treatment of Hepatitis B virus infection and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad, the company said in a release here. The estimated sale for Entecavir tablets is $166.3 million per annum. The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in financial year 2003-04.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.